Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Leaders Driving Change at SXSW: Part One

Learning about and experimenting with new products is what makes attending an event like SXSW an enjoyable and worthwhile endeavor. Hearing specific stories of how these developments have already saved lives and changed the world elevates the SXSW experience from one of intrigue to captivation. MarketScale conversed with 10 SXSW speakers about their new…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Learning about and experimenting with new products is what makes attending an event like SXSW an enjoyable and worthwhile endeavor. Hearing specific stories of how these developments have already saved lives and changed the world elevates the SXSW experience from one of intrigue to captivation.

MarketScale conversed with 10 SXSW speakers about their new products and experiences from the past year. From marketing to lifesaving surgery, this year’s conference has truly brought together some of the world’s foremost innovators in a wide gamut of industries.

Tim Brown and Nigel McAlpine

Augmented reality and 3D printing are often viewed as innovations that can enhance fun. Dr. Tim Brown Consultant Transplant Surgeon at Belfast City Hospital in Northern Ireland and Nigel McAlpine, Immersive Technology lead at Digital Catapult proved these developments can be much more impactful. Lifesaving, in fact.

Hear the story of how these two were involved in saving a young woman’s life by using 3D printing and augmented reality to rid a kidney of a tumor so that it could be transplanted into her body before it was too late.

“She didn’t have long to go, and it was very unlikely that she was going to get a transplant to save her life,” Dr. Brown said of the initial prognosis.

The pair brought to SXSW 2019 an exact replica of the donor’s kidney, which was 3D-printed by Axial3D.

“They’ve done it specially to our specifications, we’ve asked for a clear kidney and they’ve marked the tumor for us very clearly and helpfully to show us what we need chop out to make this kidney transplantable,” Dr. Brown continued.

Dr. Brown and McAlpine will be part of a panel discussing the procedure on Tuesday, March 12 at 12:30 p.m. CST.

Tatyana Kanzaveli

Tatyana Kazaveli, CEO of Open Health Network is also involved in cutting edge technology in the healthcare industry.

She helped explain how blockchain has made tangible impacts in the field and how the public can learn more about its results and move away from unsubstantiated hype.

“In healthcare I see baby steps. Mostly I see initiatives by pharma companies but there are career use cases for providers, insurance companies and pharma and researchers. But they’re still baby steps and I’m glad we’ve developed something that has actually deployed, and it does give a value as is,” she said of Open Healthcare and the state of blockchain in the medical world.

She will be elaborating on this topic on Tuesday, March 12 at 11 a.m. but gave MarketScale the lay of the land for blockchain today.

Heather Watson

Businesses must know their customer to be successful, but in this digital age, knowing how to find these customers might be more important. With Gen Z beginning to research products and order through social media and ordering products on cell phones and tablets, brands must react.

Heather Watson, behavioral designer for the Center for Generational Kinetics, LLC, has been researching how Gen Z will change the global economy, and what the next wave of workers expects from the job market, working environment and more.

“Their life digitally is as important as their physical life,” Watson said of Gen Z.

She explained how parenting, global trends and technology have transformed business and retail, and how the evolution of social media from a platform to a legitimate retail market will continue.

“One third of teenagers, or Gen Z, are on their phones after midnight every night. That is a powerful habit. They are on their phones 6-7 hours a day,” Watson said.

These habits are not going away soon, according to Watson, and marketing and advertising must learn to reach their customers in new ways.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512